Previous 10 | Next 10 |
2023-12-18 17:21:05 ET Gainers: Xeris Biopharma Holdings ( XERS ) +4% . Intuitive Machines ( LUNR ) +3% . Century Aluminum Company ( CENX ) +3% . Coherus BioSciences ( CHRS ) +2% . Independent Bank ( INDB ) +2% . Losers: ...
2023-11-17 13:32:10 ET Ever wonder what signals to look for in the stock market today? Let’s talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch. Why Insider Buying Matters in Penny S...
--News Direct-- Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share insights on the company's focus on innovative drug formulation technology after reporting strong third-quarter results. With three growing products addressing severe hypoglycemia, Cushing's Syn...
2023-11-16 10:54:48 ET Penny stocks , usually under $5 a share, draw traders looking for big gains. But these stocks can be risky. A smart move is to watch insider trading through SEC filings. Insiders like company directors and officers have access to key info that isn’t public....
2023-11-16 10:00:07 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: XWELL, Xeris B...
2023-11-09 15:17:03 ET Xeris Biopharma Holdings, Inc. (XERS) Q3 2023 Earnings Conference Call November 9, 2023 08:30 ET Company Participants Allison Wey - Senior Vice President of Investor Relations Paul Edick - Chairman & Chief Executive Officer Steven ...
2023-11-09 07:03:05 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Pharmaceuticals Q3 2023 Earnings Preview Xeris Biopharma tightens FY23 revenue v...
Achieved record revenue of $48.3M – a 27% increase from prior quarter, and a 63% increase from same period prior year Tightens full-year 2023 revenue guidance from $155M-$165M to $160M-$165M Ended Q3 with $66.0M in cash, cash equivalents and short-term investments and remai...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
2023-11-08 12:51:26 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings: On Track To Be Cash Flow Positive Xeris Biopharma's Financial Pathway: Growth Amid Challenges Xeris Biopharma tightens FY23 revenue view to $155M-$165M from $145M-$165M Seeking Alp...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...